Open Access

(+)‑Cholesten‑3‑one induces osteogenic differentiation of bone marrow mesenchymal stem cells by activating vitamin D receptor

  • Authors:
    • Qiu‑Ke Hou
    • Yong‑Quan Huang
    • Yi‑Wen Luo
    • Bin Wang
    • Ya‑Mei Liu
    • Ru‑Dong Deng
    • Sai‑Xia Zhang
    • Ying‑Tao Lai
    • Wang‑Yang Li
    • Dong‑Feng Chen
  • View Affiliations

  • Published online on: March 8, 2017     https://doi.org/10.3892/etm.2017.4200
  • Pages: 1841-1849
  • Copyright: © Hou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In our previous reports, it was revealed that steroids in traditional Chinese medicine (TCM) have the therapeutic potential to treat bone disease. In the present study, an in vitro model of a vitamin D receptor response element (VDRE) reporter gene assay in mesenchymal stem cells (MSCs) was used to identify steroids that enhanced osteogenic differentiation of MSCs. (+)‑cholesten‑3‑one (CN), which possesses a ketone group that is modified in cholesterol and cholesterol myristate, effectively promoted the activity of the VDRE promoter. Phenotypic cellular analysis indicated that CN induced differentiation of MSCs into osteogenic cells and increased expression of specific osteogenesis markers, including alkaline phosphatase, collagen II and Runt‑related transcription factor 2. Furthermore, CN significantly increased the expression of osteopontin, the target of the vitamin D receptor (VDR), which indicated that CN may activate vitamin D receptor signaling. Over‑expression of VDR or knockdown studies with VDR‑small interfering RNA revealed that the pro‑differentiation effects induced by CN required VDR. Furthermore, the present study determined that the C‑terminal region of the VDR is responsible for the action of CN. Taken together, the present findings demonstrated that CN induced osteogenic differentiation of MSCs by activating VDR. The present study explored the regulation of stem cells by using a series of similar steroids and provided evidence to support a potential strategy for the screening of novel drugs to treat bone disease in the future.
View Figures
View References

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hou QK, Huang YQ, Luo YW, Wang B, Liu YM, Deng RD, Zhang SX, Lai YT, Li WY, Chen DF, Chen DF, et al: (+)‑Cholesten‑3‑one induces osteogenic differentiation of bone marrow mesenchymal stem cells by activating vitamin D receptor. Exp Ther Med 13: 1841-1849, 2017
APA
Hou, Q., Huang, Y., Luo, Y., Wang, B., Liu, Y., Deng, R. ... Chen, D. (2017). (+)‑Cholesten‑3‑one induces osteogenic differentiation of bone marrow mesenchymal stem cells by activating vitamin D receptor. Experimental and Therapeutic Medicine, 13, 1841-1849. https://doi.org/10.3892/etm.2017.4200
MLA
Hou, Q., Huang, Y., Luo, Y., Wang, B., Liu, Y., Deng, R., Zhang, S., Lai, Y., Li, W., Chen, D."(+)‑Cholesten‑3‑one induces osteogenic differentiation of bone marrow mesenchymal stem cells by activating vitamin D receptor". Experimental and Therapeutic Medicine 13.5 (2017): 1841-1849.
Chicago
Hou, Q., Huang, Y., Luo, Y., Wang, B., Liu, Y., Deng, R., Zhang, S., Lai, Y., Li, W., Chen, D."(+)‑Cholesten‑3‑one induces osteogenic differentiation of bone marrow mesenchymal stem cells by activating vitamin D receptor". Experimental and Therapeutic Medicine 13, no. 5 (2017): 1841-1849. https://doi.org/10.3892/etm.2017.4200